Tripeptide tyroserleutide plus doxorubicin: therapeutic synergy and side effect attenuation

BACKGROUND: Tripeptide tyroserleutide (YSL) is a novel small molecule anti-tumor polypeptide that has been shown to inhibit the growth of human liver cancer cells. In this study, we investigated the effects of YSL plus doxorubicin on the growth of human hepatocellular carcinoma BEL-7402 cells that h...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Zhi-feng, Chen, Li-juan, Lu, Rong, Jia, Jing, Liang, Yu, Xu, Qiong, Zhou, Chun-lei, Wang, Li, Wang, Song, Yao, Zhi
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2601048/
https://www.ncbi.nlm.nih.gov/pubmed/19025669
http://dx.doi.org/10.1186/1471-2407-8-342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2601048/
https://www.ncbi.nlm.nih.gov/pubmed/19025669
http://dx.doi.org/10.1186/1471-2407-8-342

Ejemplares similares